MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing an AI-powered voice analysis platform designed to rapidly detect drug and alcohol impairment from short speech samples. The technology offers a non-invasive alternative to traditional breath, saliva, urine and laboratory-based testing, addressing critical safety needs in high-risk industries.
Trained on more than 50 million data points and analyzing over 140 acoustic markers, the platform aims to deliver real-time impairment assessments through Edge AI kiosks. The company plans initial field testing in 2026, with an initial commercial focus on South American mining operations, where large-scale workforce screening presents significant safety and logistical challenges.
The global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, according to industry reports. MindBio sees opportunities to expand its platform into aviation, construction, transportation, law enforcement, call centers and healthcare, leveraging its proprietary research to address the increasing demand for faster, scalable workplace impairment detection.
MindBio is a biotechnology company that is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
For more information, visit https://ibn.fm/Gw5Fa. The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF.
